CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK
R Minaa, B Dhakalb, J San-Miguelc, N Lendvaid, M Vogele, K Lif, D Cheng, N Patelh, H Einselei, J Martinez-Lopezj
a University of Torino, Turin, Italy
b Medical College of Wisconsin, Milwaukee, United States
c Cancer Center Clínica Universidad Navarra, Pamplona, Spain
d Janssen Research & Development, Raritan, United States
e Janssen Research & Development, Neuss, Germany
f Janssen Research & Development, Spring House, United States
g Janssen Research & Development, Shanghai, China
h Legend Biotech USA Inc, Somerset, United States
i Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
j Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid, Spain
Ver másRead
399
Timeswas read the article
122
Total PDF
277
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 May | 15 | 5 | 20 |
| 2025 April | 34 | 9 | 43 |
| 2025 March | 56 | 10 | 66 |
| 2025 February | 31 | 13 | 44 |
| 2025 January | 39 | 15 | 54 |
| 2024 December | 36 | 17 | 53 |
| 2024 November | 43 | 34 | 77 |
| 2024 October | 23 | 19 | 42 |
